TITLE:
Intravitreal Bevacizumab for the Treatment of Chronic or Recurrent Central Serous Chorioretinopathy
AUTHORS:
Mitzy E. Torres Soriano, Gerardo García Aguirre, Maximiliano Gordon Angelozzi, Veronica Kon Jara, Jans Fromow Guerra, Michael D. Ober, Hugo Quiroz Mercado
KEYWORDS:
Central Serous Chorioretinopathy, Intravitreal Bevacizumab, Retinal Pigment Epithelium Detachment
JOURNAL NAME:
Open Journal of Ophthalmology,
Vol.4 No.3,
July
24,
2014
ABSTRACT: Background: We report the use of intravitreal bevacizumab
as an option for the treatment of chronic or recurrent central serous chorioretinopathy
(CSC). Methods: Eight eyes with chronic or recurrent CSC received intravitreal bevacizumab
(1.25 mg/0.05 cc) and underwent best corrected visual
acuity (VA), optical coherent tomography (OCT), fluorescein angiography (FA)
and indocyanine green angiography (ICG) before, and one, three and six months
after treatment. Results: All patients showed improvement in visual acuity,
fluorescein angiographic leakage, choroidal
hyperpermeability and reduced or resolved neurosensory detachment
following treatment. Two patients require a second dose of intravitreal bevacizumab. Conclusions: Intravitreal injection of bevacizumab
was associated with visual improvement and reduced neurosensory detachment
without adverse events in patients with chronic or recurrent CSC. Although
these results are promising, further
investigations would be helpful to understand this therapy for patients with CSC.